TIF News (IT)

TIF´s brand new Webinar, entitled ”Blood Transfusion in Thalassaemia” and organised as part of the eThalED Course, will be held on Monday, 31 August 2020, 15:00-16:00 EEST / 13:00-14:00 BST.…

This Annual Report showcases the Federation’s intensive efforts that took place in 2019 with the aim to ensure equal access to quality healthcare for every patient with thalassaemia and haemoglobin…

On the occasion of today´s World Hepatitis Day and with the aim of informing and raising awareness among patients with thalassaemia – and not only – about viral hepatitis that…

Tune in for TIF’s upcoming webinar on ”Liver Disease & Thalassaemia” for Medical Specialists, organised in the context of our eThalED Course on Friday, 31 July, EEST 15:00-16:00. Prof. Geoffrey Dusheiko, Emeritus…

The swift scientific progress made in the field of thalassaemia research has gained momentum with the market authorisations of both the Zynteglo Gene Therapy by the European Medicines Agency (EMA)…

Many patients with haemoglobinopathies, including thalassaemia and sickle cell disease, are at increased risk of developing severe complications from the coronavirus disease 2019 (COVID‐19). Although epidemiologic evidence concerning the novel…

Being mindful of the COVID-19 situation and wanting to ensure participants’ safety, TIF has taken the decision to postpone its long-awaited ’15th International Conference on Thalassaemia & other Haemoglobinopathies‘ & the ’17th TIF…

The safety concerns linked to the use of DEHP plasticizers, a manufactured chemical common in blood bags and PVC intravenous fluid sets, has been explored – and even questioned –…

Patients with haemoglobin disorders, particularly β-thalassaemia or sickle cell disease (SCD) or combined forms, on account of their underlying disease pathology and associated (iron load mainly in the case of…

Millions of people worldwide suffer from inherited non-malignant blood disorders like thalassaemia and sickle cell disease. The culprit: genetic defects in their blood stem cells. One of the novel therapies …